Recent update on comprehensive therapy for advanced hepatocellular carcinoma

doi:10.4251/wjgo.v13.i8.845

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6884)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-1) series.

Item

Count

PDF

460

WORD

155

HTML

3379

Tables (1-1)

562

Sum=4556

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

686

Download

1643

Sum=2329

Aug 15, 2021 (publication date) through Oct 22, 2025

Times Cited of This Article

Times Cited (18)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Minireviews

World J Gastrointest Oncol. Aug 15, 2021; 13(8): 845-855
Published online Aug 15, 2021. doi: 10.4251/wjgo.v13.i8.845

Table 1 First and second-line treatments for advanced hepatocellular carcinoma

Systemic treatment	Drug selection
Systemic treatment	First-line drugs	Second-line drugs
Targeted therapy	Sorafenib; Lenvatinib; Donafenib	Regorafenib; Cabozantinib; Apatinib
Immunotherapy	Nivolumab; Pembrolizumab	Camrelizumab; Ramucirumab; Durvalumab
Combination therapy	Atezolizumab + Bevacizumab (Preferred)	Camrelizumab + Apatinib (Phase Ia/Ib)
	Sintilimab + Bevacizumab analogs (Phase III)	Nivolumab + Ipilimumab (Phase II)
	Camrelizumab + Apatinib (Phase II)	Nivolumab + Ipilimumab + Cabozantinib (Phase II)
	Sintilimab + Anlotinib (Phase II)
	Tremelimumab + Durvalumab (Phase II)
	Pembrolizumab + Lenvatinib (Phase Ib)
	Anlotinib + Penpulimab (Phase Ib/II)

Full Size Table

Citation: Wang H, Li W. Recent update on comprehensive therapy for advanced hepatocellular carcinoma. World J Gastrointest Oncol 2021; 13(8): 845-855
URL: https://www.wjgnet.com/1948-5204/full/v13/i8/845.htm
DOI: https://dx.doi.org/10.4251/wjgo.v13.i8.845